PPAR Research / 2009 / Article / Tab 2

Review Article

Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?

Table 2

The effect of TZDs on CV risk. The table shows a comparison between rosiglitazone and pioglitazone on lipid profile and HbA1c levels in various studies [1923].

TZDs versus placeboPioglitazoneRosiglitazone

Total cholesterolNeutralRaised
HbA1c 1–1.5% 1–1.5%

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.